Featured Research

from universities, journals, and other organizations

New technology for screening potential analgesic drugs

Date:
February 24, 2014
Source:
Universidad de Barcelona
Summary:
Researchers have developed technology that enables them to a determine drugs’ analgesic potential before being tested in animal models. The finding saves time and money on researching new effective pain treatments.

Researchers of the Neuropharmacology and Pain Research Group of the Bellvitge Biomedical Research Institute (IDIBELL), the University of Barcelona (UB) and ESTEVE, have developed  technology that enables them to a determine drugs' analgesic potential before being tested in animal models. The finding saves time and money on researching new effective pain treatments.

Traditionally in the development of analgesic drugs, the effectiveness of these molecules has been determined by using pain animal models, a hard, expensive and unclear process from a pharmacological point of view. Therefore, the great challenge is to develop more effective methodologies. Francisco Ciruela, senior lecturer of the Department of Pathology and Experimental Therapy at UB and researcher of the Neuropharmacology and Pain Research Group, explains: "We are talking about thousands of drugs; so, before testing them in preclinical pain models, that is, animal models, it will be useful to do a screening of the activity of these molecules in order to separate those that have greater antinociceptive potential."

The study led by Ciruela describes a new technology to determine the analgesic activity of drugs before being tested in animal models. "We have developed a Receptor Fluorescence Resonance Energy Transfer (FRET) based biosensor that allow us to classify in a simple system (cells in culture) ligands in sigma-1 receptor into agonists and antagonists," details the researcher.

The experiments carried out by ESTEVE and the research group led by Dr Ciruela (IDEBELL-UB) with known drugs established a direct correlation between the biosensor FRET signal in response to these drugs and their analgesic effect in a pain animal model. Results show that, whereas sigma-1 agonists reduce FRET signal and have low analgesic effects, sigma-1 antagonists increase FRET signal and have high analgesic effects in pain animal models.

"Thanks to this well-defined pattern -- explains Dr Ciruela -- , we can predict the analgesic behaviour of a molecule." Therefore, if FRET signal is reduced -- that is, if it is an agonist -- , it won't have analgesic effects on the pain animal model; however, if FRET signal is increased -- in other words, if it is an antagonist -- , it will have maximum analgesic effects and, therefore, it will be a suitable candidate to be tested in vivo.

The researcher points out that the new technology has already been patented, and "although is too early to get the most of it -- because FRET measures are now done one drug by one -- , it is expected that it will be soon applied in an extensive way to the development of analgesic antagonists sigma-1 receptor," highlights Ciruela. Therefore, the system will be robotized in order to develop a tool technically known as 'high-throughput screening' (HTS), in other words, a method to test many medicines in a quick and effective manner.

Analgesia: a subject area with many medical needs

There are two main groups of medicines in pain pharmacology: non-steroidal anti-inflammatory drugs (NSAIDs) and opioids. Each type has different action mechanisms with an 'analgesic ceiling' and different side effects. Whereas NSAIDs (for instance, ibuprofen) have a low-moderate analgesic potential and non-serious side effects, opioids (for instance, morphine) have high analgesic potential and serious side effects. So, there is an important analgesic gap, not only to present a risk-benefit favourable to treat moderate and severe pain, but also in the approach to pain treatment, a field in which medicines are not usually effective (for instance, in neuropathic pain).

ESTEVE focuses part of its R&D on active molecules for the treatment of neuropathic pain in patients receiving opioids. The main goal is to improve effectiveness, tolerance and safety and reduce side effects' frequency of this group of drugs. In this sense, to block sigma-1 receptor with specific antagonists constitutes a new mechanism of action for pain in a field that needs new treatments. Therefore, besides the selective sigma-1 receptor antagonist, E-52862, which is now in a phase II clinical trial, ESTEVE has a number of molecules with potential activity on this receptor.


Story Source:

The above story is based on materials provided by Universidad de Barcelona. Note: Materials may be edited for content and length.


Journal Reference:

  1. Maricel Gómez-Soler, Víctor Fernández-Dueñas, Enrique Portillo-Salido, Pilar Pérez, Daniel Zamanillo, José Miguel Vela, Javier Burgueño, Francisco Ciruela. Predicting the Antinociceptive Efficacy of σ1Receptor Ligands by a Novel Receptor Fluorescence Resonance Energy Transfer (FRET) Based Biosensor. Journal of Medicinal Chemistry, 2014; 57 (1): 238 DOI: 10.1021/jm401529t

Cite This Page:

Universidad de Barcelona. "New technology for screening potential analgesic drugs." ScienceDaily. ScienceDaily, 24 February 2014. <www.sciencedaily.com/releases/2014/02/140224092052.htm>.
Universidad de Barcelona. (2014, February 24). New technology for screening potential analgesic drugs. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2014/02/140224092052.htm
Universidad de Barcelona. "New technology for screening potential analgesic drugs." ScienceDaily. www.sciencedaily.com/releases/2014/02/140224092052.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) — Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Newsy (July 30, 2014) — The Peace Corps is one of several U.S.-based organizations to pull workers out of West Africa because of the Ebola outbreak. Video provided by Newsy
Powered by NewsLook.com
Weather Kills 2K A Year, But Storms Aren't The Main Offender

Weather Kills 2K A Year, But Storms Aren't The Main Offender

Newsy (July 30, 2014) — Health officials say 2,000 deaths occur each year in the U.S. due to weather, but it's excessive heat and cold that claim the most lives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:  

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile iPhone Android Web
      Follow Facebook Twitter Google+
      Subscribe RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins